<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41008575</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1268</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom15091268</ELocationID><Abstract><AbstractText Label="UNLABELLED">Dysregulation contributes to Alzheimer's disease (AD) pathophysiology. Zinc therapy promotes enterocyte copper sequestration, potentially reducing systemic copper. Individual biological responses may vary.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ZINCAiD was a 24-week, randomized, double-blind, placebo-controlled phase II trial assessing zinc therapy in individuals with mild cognitive impairment (MCI) due to AD (EudraCT No.: 2019-000604-15; registered on 26 March 2020). Participants were randomized 2:1 to receive elemental zinc (135 mg/day for 12 weeks, then 65 mg/day) or placebo. Ceruloplasmin was measured at predefined intervals for safety monitoring, blinded to the investigators. Post hoc, "Zinc Responders" were defined by &#x2265;20% reduction in ceruloplasmin at week 12. The primary cognitive endpoint was the Cognitive Composite 2 scale (CC2); secondary endpoints included MMSE and CDR-Sob.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Of the 48 participants randomized, 9 discontinued, primarily due to unrelated clinical deterioration; 39 had complete ceruloplasmin data. Two serious adverse events occurred in the Placebo group. Mild gastrointestinal symptoms occurred in eight participants, with only four leading to dropout. In the primary zinc vs. placebo analysis, no significant differences emerged in cognitive outcomes. A post hoc exploratory analysis stratified participants by pharmacodynamic response: 12 individuals with MCI due to AD (31%) met the criteria for "Zinc Responder," defined by &#x2265;20% reduction in serum ceruloplasmin at week 12. Only Zinc Responders maintained cognitive stability over 24 weeks, whereas the combined group of Zinc Non-Responders and placebo-treated participants showed a significant decline. For the composite cognitive score (CC2), the interaction between visit and response group was significant (<i>p</i> = 0.030), with deterioration observed only in the Non-Responder + Placebo group (&#x394; = -2.72, <i>p</i> &lt; 0.0001 vs. -0.71, <i>p</i> = 0.35 in Responders). Similar patterns were observed for CDR-Sob (interaction <i>p</i> = 0.017) and MMSE (trend <i>p</i> = 0.09).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Zinc therapy stabilized cognition in a pharmacodynamically defined MCI subgroup. These exploratory findings suggest serum ceruloplasmin as a feasible biomarker of target engagement. Larger trials are needed for confirmation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Squitti</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5624-1140</Identifier><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Science, Research and Development Division, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Theoretical and Applied Sciences (DISTA), eCampus University, 22100 Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8703-6940</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Clinic, Department of Medicine, Surgery and Health Sciences, Azienda Sanitaria Universitaria Giuliano Isontina, 34148 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fostinelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0120-880X</Identifier><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geviti</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0041-4142</Identifier><AffiliationInfo><Affiliation>Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivolta</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0002-1614-4861</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Hospital, 25123 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ventriglia</LastName><ForeName>Mariacarla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micera</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9375-6071</Identifier><AffiliationInfo><Affiliation>Research and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Science, IRCCS-Fondazione Bietti, 00184 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rongioletti</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Science, Research and Development Division, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7691-1957</Identifier><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santilli</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Biomedical Technologies (ITAB), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Institute, SS Annunziata University Hospital, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granzotto</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9181-4373</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Biomedical Technologies (ITAB), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Institute, SS Annunziata University Hospital, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Catholic University, 20123 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sensi</LastName><ForeName>Stefano L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-0710-2574</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Biomedical Technologies (ITAB), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Institute, SS Annunziata University Hospital, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9340-9814</Identifier><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, University of Brescia, 25121 Brescia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PTC-19-602325</GrantID><Agency>Alzheimer Association</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.16.3.1</RegistryNumber><NameOfSubstance UI="D002570">Ceruloplasmin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="Y">Zinc</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002570" MajorTopicYN="N">Ceruloplasmin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">copper</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">zinc therapy</Keyword></KeywordList><CoiStatement>Authors declare no commercial conflicts of interest relating to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41008575</ArticleId><ArticleId IdType="pmc">PMC12466942</ArticleId><ArticleId IdType="doi">10.3390/biom15091268</ArticleId><ArticleId IdType="pii">biom15091268</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Dyck C.H., Swanson C.J., Aisen P., Bateman R.J., Chen C., Gee M., Kanekiyo M., Li D., Reyderman L., Cohen S., et al. Lecanemab in Early Alzheimer&#x2019;s Disease. N. Engl. J. Med. 2023;388:9&#x2013;21. doi: 10.1056/NEJMoa2212948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2212948</ArticleId><ArticleId IdType="pubmed">36449413</ArticleId></ArticleIdList></Reference><Reference><Citation>Horncampbell C., Brown R., Linder M. Circulating ceruloplasmin is an important source of copper for normal and malignant animal cells. Biochim. Biophys. Acta (BBA)-Gen. Subj. 1981;678:27&#x2013;38. doi: 10.1016/0304-4165(81)90044-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-4165(81)90044-1</ArticleId><ArticleId IdType="pubmed">7306577</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Li A., Mei Y., Zhao J., Zhou Q., Li Y., Yang M., Xu Q. Trace elements and Alzheimer dementia in population-based studies: A bibliometric and meta-analysis. Environ. Pollut. 2022;318:120782. doi: 10.1016/j.envpol.2022.120782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envpol.2022.120782</ArticleId><ArticleId IdType="pubmed">36464120</ArticleId></ArticleIdList></Reference><Reference><Citation>Squitti R., Faller P., Hureau C., Granzotto A., White A.R., Kepp K.P. Copper Imbalance in Alzheimer&#x2019;s Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology. J. Alzheimer&#x2019;s Dis. 2021;83:23&#x2013;41. doi: 10.3233/JAD-201556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-201556</ArticleId><ArticleId IdType="pubmed">34219710</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer S.W., Wang J., Burke R. In Vivo Modeling of the Pathogenic Effect of Copper Transporter Mutations That Cause Menkes and Wilson Diseases, Motor Neuropathy, and Susceptibility to Alzheimer&#x2019;s Disease. J. Biol. Chem. 2017;292:4113&#x2013;4122. doi: 10.1074/jbc.M116.756163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.756163</ArticleId><ArticleId IdType="pmc">PMC5354492</ArticleId><ArticleId IdType="pubmed">28119449</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsvetkov P., Coy S., Petrova B., Dreishpoon M., Verma A., Abdusamad M., Rossen J., Joesch-Cohen L., Humeidi R., Spangler R.D., et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254&#x2013;1261. doi: 10.1126/science.abf0529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf0529</ArticleId><ArticleId IdType="pmc">PMC9273333</ArticleId><ArticleId IdType="pubmed">35298263</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer G.J., Dick R.D., Johnson V.D., Brunberg J.A., Kluin K.J., Fink J.K. Treatment of Wilson&#x2019;s disease with zinc: XV long-term follow-up studies. J. Lab. Clin. Med. 1998;132:264&#x2013;278. doi: 10.1016/S0022-2143(98)90039-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2143(98)90039-7</ArticleId><ArticleId IdType="pubmed">9794697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenraad T. In: Wilson Disease. 2nd ed. van Gijn J., editor. IMP; Rotterdam, The Netherlands: 2001.</Citation></Reference><Reference><Citation>Brewer G.J. Copper excess, zinc deficiency, and cognition loss in Alzheimer&#x2019;s disease. BioFactors. 2012;38:107&#x2013;113. doi: 10.1002/biof.1005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1005</ArticleId><ArticleId IdType="pubmed">22438177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B., Hampel H., Feldman H.H., Scheltens P., Aisen P., Andrieu S., Bakardjian H., Benali H., Bertram L., Blennow K., et al. Preclinical Alzheimer&#x2019;s disease: Definition, natural history, and diagnostic criteria. Alzheimer&#x2019;s Dement. 2016;12:292&#x2013;323. doi: 10.1016/j.jalz.2016.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.02.002</ArticleId><ArticleId IdType="pmc">PMC6417794</ArticleId><ArticleId IdType="pubmed">27012484</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current Concepts in Mild Cognitive Impairment. Arch. Neurol. 2001;58:1985&#x2013;1992. doi: 10.1001/archneur.58.12.1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.58.12.1985</ArticleId><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J.C. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414. doi: 10.1212/WNL.43.11.2412-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Squitti R., Pal A., Ivanova I.D., Marianetti M., Rongioletti M. CLSI Validation of Exchangeable Copper Determination in Serum by ICP-MS: A Focus on Alzheimer&#x2019;s Disease and Wilson Disease. Biomolecules. 2025;15:788. doi: 10.3390/biom15060788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom15060788</ArticleId><ArticleId IdType="pmc">PMC12190365</ArticleId><ArticleId IdType="pubmed">40563428</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan N., Samtani M.N., Farnum M., Yang E., Novak G., Grundman M., Narayan V., Dibernardo A., Alzheimer&#x2019;s Disease Neuroimaging Initiative The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimer&#x2019;s Dement. 2013;9:S21&#x2013;S31. doi: 10.1016/j.jalz.2012.05.2187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.05.2187</ArticleId><ArticleId IdType="pmc">PMC3732822</ArticleId><ArticleId IdType="pubmed">23127469</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M.F., Folstein S.E., McHugh P.R. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves P.G., Rossow K.L., Bobilya D.J. Zinc-induced metallothionein and copper metabolism in intestinal mucosa, liver, and kidney of rats. Nutr. Res. 1993;13:1419&#x2013;1431. doi: 10.1016/S0271-5317(05)80791-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0271-5317(05)80791-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer G.J., Dick R.D., Grover D.K., LeClaire V., Tseng M., Wicha M., Pienta K., Redman B.G., Jahan T., Sondak V.K., et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin. Cancer Res. 2000;6:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">10656425</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolarek C., Stremmel W. Therapie des Morbus Wilson [Therapy of Wilson disease] Z. Gastroenterol. 1999;37:293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">10378366</ArticleId></ArticleIdList></Reference><Reference><Citation>Guideline on the Investigation of Subgroups in Confirmatory Clinical Trials.  [(accessed on 29 July 2025)].  Available online:  https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf.</Citation></Reference><Reference><Citation>Brewer G.J., Hill G., Prasad A., Dick R. The Treatment of Wilson&#x2019;s Disease with Zinc. IV. Efficacy Monitoring Using Urine and Plasma Copper. Exp. Biol. Med. 1987;184:446&#x2013;455. doi: 10.3181/00379727-184-42499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-184-42499</ArticleId><ArticleId IdType="pubmed">3562454</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer G.J. Copper-2 Hypothesis for Causation of the Current Alzheimer&#x2019;s Disease Epidemic Together with Dietary Changes That Enhance the Epidemic. Chem. Res. Toxicol. 2017;30:763&#x2013;768. doi: 10.1021/acs.chemrestox.6b00373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.6b00373</ArticleId><ArticleId IdType="pubmed">28161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M.P., Cousins R.J. Isolation of an intestinal metallothionein induced by parenteral zinc. Biochem. Biophys. Res. Commun. 1977;75:286&#x2013;294. doi: 10.1016/0006-291X(77)91041-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(77)91041-5</ArticleId><ArticleId IdType="pubmed">851439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall A., Young B., Bremner I. Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat. J. Inorg. Biochem. 1979;11:57&#x2013;66. doi: 10.1016/S0162-0134(00)80054-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0162-0134(00)80054-9</ArticleId><ArticleId IdType="pubmed">479878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuzbasiyan-Gurkan V., Grider A., Nostrant T., Cousins R.J., Brewer G.J. Treatment of Wilson&#x2019;s disease with zinc: X. Intestinal metallothionein induction. J. Lab. Clin. Med. 1992;120:380&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1517684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenraad T.U., Squitti R. Paradigm Shift in Treatment of Alzheimer&#x2032;s Disease: Zinc Therapy Now a Conscientious Choice for Care of Individual Patients. Int. J. Alzheimer&#x2019;s Dis. 2011;2011:492686. doi: 10.4061/2011/492686.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2011/492686</ArticleId><ArticleId IdType="pmc">PMC3178199</ArticleId><ArticleId IdType="pubmed">21949909</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S., Cummings J., Knox S., Potashman M., Harrison J. Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer&#x2019;s Disease. J. Prev. Alzheimer&#x2019;s Dis. 2022;9:507&#x2013;522. doi: 10.14283/jpad.2022.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2022.41</ArticleId><ArticleId IdType="pmc">PMC9843702</ArticleId><ArticleId IdType="pubmed">35841252</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch G., Casula E.P., Bonn&#xec; S., Borghi I., Assogna M., Minei M., Pellicciari M.C., Motta C., D&#x2019;aCunto A., Porrazzini F., et al. Precuneus magnetic stimulation for Alzheimer&#x2019;s disease: A randomized, sham-controlled trial. Brain. 2022;145:3776&#x2013;3786. doi: 10.1093/brain/awac285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac285</ArticleId><ArticleId IdType="pmc">PMC9679166</ArticleId><ArticleId IdType="pubmed">36281767</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcellini F., Giuli C., Papa R., Gagliardi C., Dedoussis G., Herbein G., Fulop T., Monti D., Rink L., Jajte J., et al. Zinc status, psychological and nutritional assessment in old people recruited in five European countries: Zincage study. Biogerontology. 2006;7:339&#x2013;345. doi: 10.1007/s10522-006-9048-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10522-006-9048-4</ArticleId><ArticleId IdType="pubmed">16969711</ArticleId></ArticleIdList></Reference><Reference><Citation>Young B., Ott L., Kasarskis E., Rapp R., Moles K., Dempsey R.J., Tibbs P.A., Kryscio R., McCLAIN C. Zinc Supplementation Is Associated with Improved Neurologic Recovery Rate and Visceral Protein Levels of Patients with Severe Closed Head Injury. J. Neurotrauma. 1996;13:25&#x2013;34. doi: 10.1089/neu.1996.13.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.1996.13.25</ArticleId><ArticleId IdType="pubmed">8714860</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazdouz M., Mazidi M., Ehsaei M.-R., Ferns G., Kengne A.P., Norouzy A.-R. Impact of Zinc Supplementation on the Clinical Outcomes of Patients with Severe Head Trauma: A Double-Blind Randomized Clinical Trial. J. Diet. Suppl. 2017;15:1&#x2013;10. doi: 10.1080/19390211.2017.1304486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2017.1304486</ArticleId><ArticleId IdType="pubmed">28467150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarris J., Ravindran A., Yatham L.N., Marx W., Rucklidge J.J., McIntyre R.S., Akhondzadeh S., Benedetti F., Caneo C., Cramer H., et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J. Biol. Psychiatry. 2022;23:424&#x2013;455. doi: 10.1080/15622975.2021.2013041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15622975.2021.2013041</ArticleId><ArticleId IdType="pubmed">35311615</ArticleId></ArticleIdList></Reference><Reference><Citation>Avan A., Squitti R., Gaskin S., Cz&#x142;onkowska A. A tribute to Tjaard Hoogenraad. Lancet Neurol. 2022;21:505&#x2013;506. doi: 10.1016/S1474-4422(22)00186-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00186-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Zhang Y.H., Guo C., Gao H.L., Zhong M.L., Huang T.T., Liu N.N., Guo R.F., Lan T., Zhang W., et al. Tetrathiomolybdate Treatment Leads to the Suppression of Inflammatory Responses through the TRAF6/NF&#x3ba;B Pathway in LPS-Stimulated BV-2 Microglia. Front. Aging Neurosci. 2018;10:9. doi: 10.3389/fnagi.2018.00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00009</ArticleId><ArticleId IdType="pmc">PMC5835334</ArticleId><ArticleId IdType="pubmed">29535623</ArticleId></ArticleIdList></Reference><Reference><Citation>Okafor M., Champomier O., Raibaut L., Ozkan S., El Kholti N., Ory S., Chasserot-Golaz S., Gasman S., Hureau C., Faller P., et al. Restoring cellular copper homeostasis in Alzheimer disease: A novel peptide shuttle is internalized by an ATP-dependent endocytosis pathway involving Rab5- and Rab14-endosomes. Front. Mol. Biosci. 2024;11:1355963. doi: 10.3389/fmolb.2024.1355963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2024.1355963</ArticleId><ArticleId IdType="pmc">PMC11026709</ArticleId><ArticleId IdType="pubmed">38645276</ArticleId></ArticleIdList></Reference><Reference><Citation>Fashami M.Z., Bajelan A., Shakur H., Khakpai F., Rouhollah F., Vaseghi S., Yekta B.G. The Effect of Zeolite Zinc on Memory Performance and Hippocampal Cell Death in a Rat Model of Alzheimer&#x2019;s-like Disease Induced by A&#x3b2;1&#x2013;42. Biol. Trace Elem. Res. 2024;203:4211&#x2013;4223. doi: 10.1007/s12011-024-04474-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-024-04474-0</ArticleId><ArticleId IdType="pubmed">39643797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabanez M., Santos I.R., Ikebara J.M., Camargo M.L.M., Dos Santos B.A., Freire B.M., Batista B.L., Takada S.H., Squitti R., Kihara A.H., et al. The Impact of Hydroxytyrosol on the Metallomic-Profile in an Animal Model of Alzheimer&#x2019;s Disease. Int. J. Mol. Sci. 2023;24:14950. doi: 10.3390/ijms241914950.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241914950</ArticleId><ArticleId IdType="pmc">PMC10573659</ArticleId><ArticleId IdType="pubmed">37834398</ArticleId></ArticleIdList></Reference><Reference><Citation>Marianetti M., Pinna S., Venuti A., Liguri G. Olive polyphenols and bioavailable glutathione: Promising results in patients diagnosed with mild Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2022;13:e12278. doi: 10.1002/trc2.12278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12278</ArticleId><ArticleId IdType="pmc">PMC8918095</ArticleId><ArticleId IdType="pubmed">35310529</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>